You are here: Urology Textbook > Drugs in Urology > Alpha-blocker > Silodosin
Alpha-blocker (5/6): Silodosin
- Alpha-blocker (1/6): General pharmacology
- Alpha-blocker (2/6): Terazosin
- Alpha-blocker (3/6): Doxazosin
- Alpha-blocker (4/6): Tamsulosin
- Alpha-blocker (5/6): Alfuzosin
- Alpha-blocker (6/6): Silodosin
Review Literatur: (Chapple, 2004).
General Pharmacology of Silodosin
Mechanism of Action of Silodosin
Silodosin is a new selective alpha1A-blocker with a favourable cardiovascular side effect rate (Cantrell et al, 2010). Alpha-blocker are used for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Please see section general pharmacology of alpha-blocker.
Pharmacokinetics of Silodosin
Bioavailability 32%, high plasma protein binding, hepatic metabolization, elimination half life 13 h, biliary and renal excretion of metabolites.
General Side Effects of Alpha-Blocker
- Hypotension, orthostatic syncope, reflex tachycardia
- Stuffy nose
- Retrograde ejaculation
- Dizziness, weakness
- Overall rate of side effects is between 10–30%, selective alpha1A-blocker like silodosin have a reduced cardiac side effect rate.
Contraindications of Alpha-Blocker
Urological Contraindications:
Conservative treatment of BPH is not indicated, if surgical treatment is imperative: chronic urinary retention with renal failure, recurrent hematuria due to prostatic enlargement, recurrent infections and bladder stones.
Cardiac Contraindications:
Hypotension, mechanical heart failure (valvular, pulmonary embolism, pericarditis), congestive heart failure.
Other contraindications:
Silodosin should be paused perioperatively for cataract surgery to prevent an intraoperative floppy iris syndrome.
Specific Contraindications of Silodosin
- Severe renal insufficiency (<30 ml/min)
- Children
- Inhibitors of CYP3A4 like ketoconazol
Dosage of Silodosin
8 mg 1-0-0. Reduce dosage to 4 mg in patients with renal insufficiency (<50 ml/min).
Alfuzosin | Index | Pharmacology |
Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
References
- Cantrell, M. A.; Bream-Rouwenhorst, H. R.; Hemerson, P. & Magera, J. S.
- Silodosin for benign prostatic hyperplasia.
Ann Pharmacother, 2010, 44, 302-310. - Chapple 2004 CHAPPLE, C. R.:
- Pharmacological therapy of benign prostatic hyperplasia/lower urinary
tract symptoms: an overview for the practising clinician.
In: BJU Int
94 (2004), Nr. 5, S. 738–44
Deutsche Version: Silodosin